The tumor volumes (left panel) of T cell-treated CD200-positive tumors were significantly smaller and the survival times of mice with CD200-positive tumors were significantly longer compared to mice with CD200-negtive tumors receiving the same T cell treatment (right panel). The gene discussed is CD200; the disease is neoplasm.